Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 09:26:06 UTC |
---|
Update Date | 2021-09-26 23:04:03 UTC |
---|
HMDB ID | HMDB0251810 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Eniluracil |
---|
Description | Eniluracil belongs to the class of organic compounds known as pyrimidones. Pyrimidones are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions. Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). Eniluracil is a drug which is used for the treatment of cancer in combination with 5-fluorouracil. Eniluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug. Eniluracil is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor, designed to enhance activity of chemotaxic agents. Eniluracil is an extremely weak basic (essentially neutral) compound (based on its pKa). Eniluracil has received Orphan Drug status from the FDA for the treatment of hepatocellular cancer in combination with fluoropyrimidines (including 5-FU). Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety of cancers including colorectal, breast, gastric, head and neck, ovarian and basal cell cancer of the skin. It is under investigation by Adherex, under license from GlaxoSmithKline, for the treatment of cancer in combination with 5-fluorouracil (5-FU). Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available. This compound has been identified in human blood as reported by (PMID: 31557052 ). Eniluracil is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Eniluracil is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10) |
---|
Synonyms | Value | Source |
---|
776c85 | ChEMBL | 5-Ethynyluracil | MeSH | Compound 776C | MeSH |
|
---|
Chemical Formula | C6H4N2O2 |
---|
Average Molecular Weight | 136.1082 |
---|
Monoisotopic Molecular Weight | 136.027277382 |
---|
IUPAC Name | 5-ethynyl-1,2,3,4-tetrahydropyrimidine-2,4-dione |
---|
Traditional Name | 5-ethynyluracil |
---|
CAS Registry Number | Not Available |
---|
SMILES | O=C1NC=C(C#C)C(=O)N1 |
---|
InChI Identifier | InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10) |
---|
InChI Key | JOZGNYDSEBIJDH-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyrimidones. Pyrimidones are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazines |
---|
Sub Class | Pyrimidines and pyrimidine derivatives |
---|
Direct Parent | Pyrimidones |
---|
Alternative Parents | |
---|
Substituents | - Pyrimidone
- Hydropyrimidine
- Vinylogous amide
- Heteroaromatic compound
- Lactam
- Urea
- Acetylide
- Azacycle
- Organic oxide
- Organopnictogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Eniluracil,1TMS,isomer #1 | C#CC1=CN([Si](C)(C)C)C(=O)[NH]C1=O | 1679.1 | Semi standard non polar | 33892256 | Eniluracil,1TMS,isomer #1 | C#CC1=CN([Si](C)(C)C)C(=O)[NH]C1=O | 1567.7 | Standard non polar | 33892256 | Eniluracil,1TMS,isomer #1 | C#CC1=CN([Si](C)(C)C)C(=O)[NH]C1=O | 2267.0 | Standard polar | 33892256 | Eniluracil,1TMS,isomer #2 | C#CC1=C[NH]C(=O)N([Si](C)(C)C)C1=O | 1618.5 | Semi standard non polar | 33892256 | Eniluracil,1TMS,isomer #2 | C#CC1=C[NH]C(=O)N([Si](C)(C)C)C1=O | 1569.2 | Standard non polar | 33892256 | Eniluracil,1TMS,isomer #2 | C#CC1=C[NH]C(=O)N([Si](C)(C)C)C1=O | 2230.0 | Standard polar | 33892256 | Eniluracil,2TMS,isomer #1 | C#CC1=CN([Si](C)(C)C)C(=O)N([Si](C)(C)C)C1=O | 1814.1 | Semi standard non polar | 33892256 | Eniluracil,2TMS,isomer #1 | C#CC1=CN([Si](C)(C)C)C(=O)N([Si](C)(C)C)C1=O | 1722.5 | Standard non polar | 33892256 | Eniluracil,2TMS,isomer #1 | C#CC1=CN([Si](C)(C)C)C(=O)N([Si](C)(C)C)C1=O | 2059.9 | Standard polar | 33892256 | Eniluracil,1TBDMS,isomer #1 | C#CC1=CN([Si](C)(C)C(C)(C)C)C(=O)[NH]C1=O | 1923.8 | Semi standard non polar | 33892256 | Eniluracil,1TBDMS,isomer #1 | C#CC1=CN([Si](C)(C)C(C)(C)C)C(=O)[NH]C1=O | 1808.5 | Standard non polar | 33892256 | Eniluracil,1TBDMS,isomer #1 | C#CC1=CN([Si](C)(C)C(C)(C)C)C(=O)[NH]C1=O | 2357.1 | Standard polar | 33892256 | Eniluracil,1TBDMS,isomer #2 | C#CC1=C[NH]C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 1825.8 | Semi standard non polar | 33892256 | Eniluracil,1TBDMS,isomer #2 | C#CC1=C[NH]C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 1808.0 | Standard non polar | 33892256 | Eniluracil,1TBDMS,isomer #2 | C#CC1=C[NH]C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2309.2 | Standard polar | 33892256 | Eniluracil,2TBDMS,isomer #1 | C#CC1=CN([Si](C)(C)C(C)(C)C)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2129.0 | Semi standard non polar | 33892256 | Eniluracil,2TBDMS,isomer #1 | C#CC1=CN([Si](C)(C)C(C)(C)C)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2154.3 | Standard non polar | 33892256 | Eniluracil,2TBDMS,isomer #1 | C#CC1=CN([Si](C)(C)C(C)(C)C)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2224.1 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Eniluracil GC-MS (Non-derivatized) - 70eV, Positive | splash10-000i-8900000000-dd78f7511ef0363019ea | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Eniluracil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 10V, Positive-QTOF | splash10-000i-0900000000-91f69a9c7425d6654254 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 20V, Positive-QTOF | splash10-00ko-9400000000-eb40a8fc8f91fb98cccf | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 40V, Positive-QTOF | splash10-00kf-9000000000-16a33dacd870a54266ce | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 10V, Negative-QTOF | splash10-000l-7900000000-59cd76042099a05be418 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 20V, Negative-QTOF | splash10-0006-9000000000-21295633deb9b38ed3e3 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 40V, Negative-QTOF | splash10-0006-9000000000-46955e1a964154bcde69 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 10V, Positive-QTOF | splash10-000i-1900000000-8262de422e825bf6ae45 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 20V, Positive-QTOF | splash10-00kv-9200000000-0cc027a8755e27b7cac8 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 40V, Positive-QTOF | splash10-0002-9000000000-8246c659a113d53d4d1d | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 10V, Negative-QTOF | splash10-000i-5900000000-520ed84c90966de174a5 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 20V, Negative-QTOF | splash10-0006-9000000000-c0461c2f89ca9cb548ae | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Eniluracil 40V, Negative-QTOF | splash10-0006-9000000000-fd5b628f5d050c101042 | 2021-10-12 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum |
|
---|